Sun Pharmaceutical Industries Limited

By: Pharma Tips | Views: 46061 | Date: 20-Jun-2012

Sun Pharma began in 1983 with just 5 products to treat psychiatry ailments. Sales were initially limited to two states in Eastern India. Sales were rolled out natiowide in 1985. Products for cardiology were introduced in 1987, and Monotrate, one of the first products launched then, countinues to be sold even today. Important products in Cardiology were later added; several of these introduced for the first time in India, and these brought patients the latest treatments at a sensible cost, a belief we've alw

Sun Pharmaceutical Industries Limited

PROFILE


We are an international speciality pharma company, with a large presence in the US and India,  and a footprint across  40 other markets.   

In the US, which is our largest market, we have built a strong  pipeline of generics, directly and through our subsidiaries Caraco and Sun Pharmaceutical Inc. Taro adds strong dermatology range to this portfolio.

In India and rest of the world markets, our brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology etc. We are market leaders in speciality therapy areas in India.

We retain the drive for growth that marked our early days, when we had. begun in 1983 with just 5 products. Since then, we have crossed several milestones to emerge as a leading pharma company in India where we are the 6th  largest by prescription sales, a  rank that we have retained over a decade. (IMS ORG Stockist Audit, Sept. 2010)

 

Since the mid- nineties, we have used a combination of growth and acquisition to drive growth. important acquisitions have included those of the US, detroit-based Caraco Parma Labs and a plant at Halol which now holds UKMHRA and USFDA approvals. The 2010 acquisition of Taro Pharmaceuticals doubles our US business and brings us strengths in dermatology and pediatrics.

GROUP COMPANIES

Caraco Pharmaceutical Laboratories

Based in Detroit, Michigan, Caraco develops and manufactures generic pharmaceuticals and markets them throughout the United States. The corporation's present portfolio consists of a number of products in various strengths and package sizes across therapeutic segments.

Caraco's manufacturing facility and executive offices were constructed in 1991, after a $9.1 million loan from the Economic Development Corporation of the city of Detroit. Since August 1997, capital infusions and loans have primarily come from Sun Pharma. Sun Pharma has also acted as a guarantor on loans to Caraco, has supplied the corporation with raw material for certain products, assisted in obtaining machinery and equipment to enhance production capacities, and has transferred certain generic products. Sun Pharma's investment in and support of Caraco has resulted in, since the second quarter of 2002, Caraco achieving the sales to support its operations. As of June 2011, Sun Pharma owns 100% on a diluted basis, of the outstanding common shares of Caraco.


Sun Pharmaceutical Industries Inc.

Sun Pharmaceutical Industries Inc is a Michigan Corporation and a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd, India. Sun Pharma Inc.manufactures distributes pharmaceuticals both in the United States and internationally.

In 2004, Sun Pharma acquired the trademarks, manufacturing know'how and other intellectual property of some brands from Women's First Healthcare, Inc, These products were later assigned to Sun Pharma Inc.

In December 2005, Sun Pharma Inc completed the purchase of dosage from manufacturing operations of Able Labs for USD 23.15 million. This facility has the capacity to make controlled substance dosage forms.

Sun Pharmaceutical (Bangladesh)

Sun Pharmaceutical (Bangladesh) is a private limited company, owns and operates a pharmaceutical factory and makes pharmaceutical products that are sold in the local market. The company began commercial operations in 2004.

This is partnership between Sun Pharma/ subsidiaries and City Overseas Ltd, a company incorporated in Bangladesh.
Alkaloida Chemical Company Exclusive Group Ltd.

ICN Hungary, purchased from Valeant Pharmaceuticals in 2005, is one of the few units worldwide, authorized to make controlled substances. ICN Hungary has now been renamed Alkaloida Chemical Company. This 170 acre site has facilities spread over 1,75,000 sq ft for the manufacture of bulk actives, with 500 KL capacity and designated areas to make controlled substances. It has a 150,000 sq ft facility for different dosage forms such as film coated and effervescent tablets, capsules, etc. A large 65,000 sq ft research center has labs across synthetic chemistry, instrumentation analytical and structural elucidation. The site is operational with 450 people and additional recruitments are planned over time

Chattem Chemicals

In 2008, Sun Pharma Inc. acquired Chattem Chemicals, Inc. a Chattanooga, Tennessee-based narcotic raw material importer and a DEA licensed API manufacturer of controlled substances.



Taro Pharmaceutical Industries Ltd.

Sun Pharma acquired a controlling stake in Taro in September 2010 after completing an option agreement first entered into in 2007 with the controlling shareholders of Taro. Sun's subsidiaries have subsequently increased their economic interest in Taro to 66%. Taro has an established franchise in dermatology and topical products in the US, in addtion to other generic products. Taro has sales and marketing operations in Israel and Canada.

HISTORY

Sun Pharma began in 1983 with just 5 products to treat psychiatry ailments. Sales were initially limited to two states in Eastern India. Sales were rolled out natiowide in 1985. Products for cardiology were introduced in 1987, and Monotrate, one of the first products launched then, countinues to be sold even today. Important products in Cardiology were later added; several of these introduced for the first time in India, and these brought patients the latest treatments at a sensible cost, a belief we've always lived by.

Realizing the fact that research is a critical growth driver, we established our  first research center, SPARC, in 1993 and this created the base for strong product and process development that enabled growth in the subsequent years.

Sun Pharma was listed on the main stock exchanges in India in 1994; and the Rs. 55 crore issue of a Rs. 10 face value equity share offered at a premium of Rs. 140/-, was oversubscribed 55 times. The minimum 25% that was required under the regulations then for listing was offered to the public, the founder's family continues to hold a majority stake in Sun Pharma.

We used this money to build a greenfield site for API manufacture, as well as for acquisitions. For allowed acquisitions, typically companies or assets that allowed us entry into a new market or therapy area, assets that could be turned around and  brought on track were identified.

Our first API manufacturing plant was built in Panoli in 1995, for access to high quality actives ahead of competition, and in order to tap the vast international opportunity for speciality APIs.

Another API plant, our Ahmednagar plant, was acquired from the multinational Knoll Pharmaceuticals in 1996, and expanded and substantially upgraded for regulated markets, with capacity addition over the years across differentiated API lines such as anticancers and peptides. This was the first several sensibly priced acquisitions, each of which would bring important parts to our long-term strategy.

In 1997, our headquarters shifted to Mumbai, India's commercial capital. We began the first of our international acquisitions with an initial $7.5 million investment in Caraco, Detroit. By 2000, we had completed 8 acquisitions, each such move adding new therapy areas or offering an entry to important international markets. A new research center was set up in Mumbai for generic product development for the US market. In India, as new therapy areas were entered into post acquisition; customer attention, product selection and focused marketing helped us gain a foothold in areas like orthopedics, gynecology, oncology, etc. From a ranking at 38th in 1994, by 2000 we were ranked 5th with a leadership in 8 of the 11 therapy areas that we are present in. The year 2000 was the year of turnaround at the US subsidiary, Caraco, as it began to receive approvals after successful inspection by the USFDA.

In December 2004, a research center spread over 16 acres was inaugurated by the President of India, with special lab space for drug discovery and innovation. The post 2005 years have witnessed important acquisitions to strengthen our US business- the purchase of manufacturing assets for controlled substances in Cranbury,NJ; that of a site to make creams and lotions in Bryan, that of Alkaloida, a Hungary based API and dosage form manufacturer , and, Chattem Ltd., a Tennessee-based controlled substance API manufacturer.

In September 2010 acquisition of Taro Pharmaceuticals doubled the size of our US business and brought us a range of generics including a strong line of dermatologicals. Taro's manufacturing facilities in Israel and Canada substantially add to our production capacity.

The tally at the end of 2010:
    23 manufacturing plants in 3 continents
    9000  employees
    4 World class research centers
    Brand in markets worldwide
    A strong presence in the US generic market
    Increasing research investments
    Over 58% of sales from international markets


1983
Sun Pharma began operations in Kolkata with five psychiatry - based products, first with two people and then with a ten employee team. Year 1 turnover - Rs. 1 million. Within a year, the marketing effort expand to cover all the eastern states of India. A compact manufacturing facility for tablets/capsules was set up at Vapi.

1986
Administrative office was set up in Mumbai. Customer coverage was extended to select cities in Western India.

1987
Marketing operations were rolled out nation-wide.

1988
With the introduction of Monotrate and Angizem, the first few cardiology products were launched. We featured for the first time in a market audit by the prescription tracking company, ORG (later IMS ORG) at rank 107th with 0.1% market share.

1989
The corporate office moved to Baroda, Gujarat. Products used in gastroenterology were introduced. Exports to neighboring countries began.

1991
Construction began at the first research center SPARC (Sun Pharma Advanced Research center), with 46,000 sq ft of research space, and investments of almost the size of that year's profits. The company's turnover was Rs. 9.74 cr, and market rank 70th.

1993
SPARC, the first research center, was inaugurated by His Excellency Shri K. R. Narayanan, the Vice President of India. An office began operations in Moscow. Products were registered across 10 markets in all.

1994
After our IPO in October, we were listed on the major stock exchanges in India. The offering was oversubscribed 55 times. A dosage form plant at Silvassa started production. Major expansion at the plant was Vapi was completed. For the first time, a brand from the company, Monotrate, featured among the top 250 pharma brands in the Indian market. A separate division, Synergy, was carved out to market Psychiatry/ Neurology products, the first of focused marketing divisions.

1995
Our first API plant at Panoli started production.
A new division, Azura, was begun for cardiology products. Inca, a new division to market critical care medication to intensive care units began operations. International marketing was strengthened with offices in Ukraine and Belarus.

1996
An API-manufacturing unit at Ahmednagar, the first of the our acquisitions, was bought from Knoll Pharma. An equity stake was also picked up in Gujarat Lyka Organics Ltd., a manufacturer of Cephalexin Active with a USFDA approval for the intermediate, 7ADCA. At the close of the year, we ranked 27th with 2 products among the country's top selling 300 pharma brands. Product registrations were in place across 24 countries.

1997
We began the first of our international acquisitions. As part of a technology-for-equity agreement, a stake was acquired in a generic dosage form manufacturer; the Detroit-based Caraco Pharm Labs. An equity stake was taken in MJ Pharma, a manufacturer of several dosage form lines with UK MHRA approval for Cephalexin capsules.
TDPL, a company with an extensive product offering (oncology, fertility, anesthesiology, pain management) was acquired, and its portfolio streamlined. TDPL's products offered a ready entry with known brands and customer equity in new high growth therapy areas like oncology and gynecology. Marketing was reorganized into 6 speciality-focused divisions. A research and development facility over 6,000 sq ft in Mumbai, our second research site, was set up to make dosage forms and create supporting technical documentation for the generic markets in North America and Europe.

1998
A basket of products, including several respiratory/asthma brands were acquired from Natco Pharma. Our new formulation plant at Silvassa commenced operations.

1999
Rank moved within the top 10 in the domestic market. An ophthalmology products company, Milmet Labs, was acquired Cephalexin API manufacturer Gujarat Lyka Organics was merged with Sun Pharma. 6 brands featured among the leading 300 prescription pharma brands in India.

2000
Ranked 5th among all companies in the domestic market. Pradeep Drug company, a Chennai based API manufacturer was acquired.

2001
A new formulation plant was built in Dadra. This new plant, spread over a 5-acre site with built up area of 120,000-sq. ft. was designed and built to comply with international regulatory requirements, such as the UKMHRA and USFDA.
The erstwhile TDPL division was renamed Spectra. A new division, Arian, targeting cardiologists/physicians and diabetologists, was launched.

2002
Forbes Global ranked Sun Pharma in the list of best small 200 companies for 2002 (turnover less than $500 million).
Sun Pharma was selected as the best company by Express Pharma Pulse, for overall performance for 2002 (in the category A - market share over 2.5%). 4 manufacturing sites won the prestigious IDMA awards. Work commenced on a new, state-of-the-art drug discovery campus in Baroda; this 16-acre site, with space for 600+ scientists, would be commissioned over the next two years. Work began on a new R&D center in Mumbai, with 50,000 sq. ft. floor area for product development for the North American and European markets.

2003
Forbes Global ranked Sun Pharma in the list of the best small 200 companies for 2003 (turnover less than $500million)
Sun Pharma was rated amongst the best-managed companies for 2003 across all sectors. (Business Today-AT Kearney study of best-managed companies)

2004
We acquired common stock and options from 2 large shareholders of Caraco, increasing stake to over 60% from 44% at a total outlay of about $42 million.
The upgraded and expanded formulation site in Halol, India (the erstwhile MJ Pharma site) received approval from USFDA, UK MHRA, South African MCC, Brazilian ANVISA and Columbian INVIMA.
The BT Stern Stewart survey placed Sun Pharma among the top 20 wealth creators in India and among the top 3 wealth creators in the pharma sector.
Construction at a formulation manufacturing site at Jammu was completed.
Our first joint venture manufacturing unit, in Dhaka, Bangladesh was commissioned.
Two of our API factories received USFDA approval, taking the total number of US FDA approved sites to three.
We acquired a Cephalosporin Active manufacturer, Phlox Pharma, with European approval for cefuroxime axetil amorphous.
Niche brands Ortho-Estin (estropipate) and antimigraine preparation Midrin were bought from the San Diego, US based Women-s First Healthcare. (WFHC, not listed).
Forbes Global ranked Sun Pharma in the list of most valuable companies for 2004 (turnover less than $2bill).

2005
We bought a plant in Bryan, Ohio, US and the business of ICN, Hungary from Valeant Pharma.
We acquired the intellectual property and assets of Able Labs from the US District Bankruptcy court in New Jersey in December 2005.
Dilip Shanghvi, our CMD, received the E&Y Entrepreneur of the Year award in healthcare and life sciences for 2005.
Sun Pharma was selected by Forbes amongst the best 200 companies (sales less than USD 1 billion) in Asia.

2006
We announced the demerger of innovative research and business with pipelines, people, equipment and funding, into a new company.

2007
We completed the demerger of the innovative business, with requisite legal and regulatory approvals. SPARC Ltd, the new company, was listed on the stock exchanges in India, the first pure research company to be so listed.
In May 2007, we, along with our subsidiaries, signed definitive agreements to acquire Taro Pharmaceutical Industries Ltd., (TAROF, Pink Sheets), a multinational generic manufacturer with established subsidiaries, manufacturing and products across the U.S., Israel, Canada for $454 mill. This all-cash deal was subject to Taro shareholder approval and requisite regulatory clearances.

2008

Chattem Limited
In November 2008, we along with our subsidiaries acquired 100% ownership of Chattem Chemicals, Inc., a narcotic raw material importer and manufacturer of controlled substances with an approved API facility in Tennessee. This offers vertical integration for our controlled substance dosage form business in the US.
2010
In the first week of September, the Supreme Court of Israel unanimously dismissed the appeal by Taro of the previous ruling by the Tel-Aviv District Court holding that the Israeli special tender offer (STO) rules do not apply to the Tender Offer by Suns subsidiary, Alkaloida, to purchase all outstanding Ordinary Shares of Taro. In the last week of September: we completed the acquisition of a controlling stake in Taro and increased economic interest and their voting rights. This doubles the size of our US business.

2011
Dilip Shanghvi, our CMD, received the E&Y Entrepreneur of the Year Award for 2010. (ORG - Operations Research Group Audit of Retail Chemist Sales, later renamed the IMS - ORG Retail Store Audit. Both ORG and IMS are the trademarks of their registered owners)

ACQUISITIONS


Taro Pharma
May 2007. Completed in September 2010

Announcement of acquisition

We, along with our subsidiaries, signed definitive agreements to acquire Taro Pharmaceutical Industries Ltd., (TAROF, Pink Sheets), a multinational generic manufacturer with established subsidiaries, manufacturing and products across the U.S., Israel, Canada. North America represents more than 90% of Taro's sales. Taro has a strong franchise in dermatology and topical products, in addition to product baskets in cardiovasculer, neuropsychiatric and anti-inflammatory therapeutic categories. Taro US has more than 100 ANDA drug approvals in the U.S. alone. One NDA as well as 26 ANDA are awaiting with the USFDA.

In first week of September 2010, the Supreme Court of Israel unanimously dismissed the appeal by Taro of the previous ruling by the Tel-Aviv District Court holding that the Israeli special tender offer (STO) rules do not apply for the Tender Offer by Sun's subsidiary, Alkaloida, to purchase all outstanding Ordinary Shares of Taro. In the last week of September: we completed the acquisition of a controlling stake in Taro and increased economic interest and their voting rights. This doubles the size of our US business


Chattem Limited

November 2008

We along with our subsidiaries, acquired 100% ownership of Chattem Chemicals, Inc.,a narcotic raw material importer and manufacturer of controlled substances with an API facility in Tennessee.

Able Labs
Assets only, December 2005

Dosage form manufacturing facilities spanning 2,50,000 sq ft with specifically designed areas to handle the manufacture of controlled substance dosage forms, were acquired for $23.15 million, from the US Bankruptcy Court of the District of New Jersey. This deal also includes the rights to product dossiers that were being marketed by Able,


ICN, Hungary (2005) and a manufacturing plant in Bryan, Ohio
2005

A plant in Hungary, ICN Hungary (known the world over as Alkaloida), one of the few sites globally that is authorized to make controlled substance APIs, was bought from Valeant Pharmaceuticals (NYSE:VRX). This 170 acre site with a 70-year manufacturing history, has facilities spread over 1,75,000 sq ft for the manufacture of APIs, as well as designated areas to make controlled substances. It also has facilities for dosage form manufacture and a large research center. Streamlining of operations, filing for the developed markets and addressing developed market customers is some of the steps that have been put into place as part of the turnaround.

Another facility in Ohio, US, for the manufacture of liquids, creams and ointments was also bought from Valeant, in order to file for interesting products in this area.


Niche brands purchased from Women's First Healthcare
2004

Niche brands were bought from the San Diego, US, based Women's First Healthcare (WFHC, not listed) for less then $4 million. These brands are the gynaecological Ortho-Estrin (estropipate), and the antimigraine preparation Midrin (isometheptene, acetaminophen, dichloralphenazone). In 2001, WFHC had acquired the US rights for Ortho-Estrin, Midrin and one more product, for a total of $25.7 million plus royalty payments.

Phlox Pharma
Merged 2004

Phlox Pharma, an API manufacturing pharma company, has a plant for Cephalosporins in Baroda District. This plant is approved for European markets for Cefuroxime axetil amorphous. Filings for additional Cephalosporin-based actives can be made out of this site. Substantial capacity addition has been completed and facilities meeting international regulatory requirements have been created for sterile and non-sterile Cephalosporin formulations. This site recently received USFDA approval.


Pradeep Drug Company Ltd
Acquisition, 2000

This WHO cGMP approved API manufacturing site for India and neighbouring markets was upgraded and has subsequently received ISO 9002 and 14001 certification.


Milmet Labs
Acquisition, 1999

Milmet's presence in ophthalmology with well-trusted brands like Viscomet (used in major eye surgeries) and Timolet (for glaucoma) made it an attractive acquisition candidate. New products were brought in, several of which used complex delivery technologies such as gel forming systems, the portfolio was revamped, and coverage improved, susequently rank moved to number 1 by prescription share.


Brands from Natco Pharma
Brand buyout, 1998

A basket of brands in the respiratory/chest therapy area as also brands in gastroenterology, orthopedics, anti-infectives and pediatrics were acquired. In line with the company's strategy of reorienting brands so that they can offer the best value, these brands were shifted into different divisions, doctor call-lists were reworked and new products added backed by strong promotional programs.


Caraco
Subsidiary-initial equity stake 1997, incremental stake increases 1997-2003, larger stake buyout 2004 Going private proposal 2010

view Caraco's site.

Caraco Pharmaceutical Laboratories (CPD: Amex) is a Detroit, US based manufacturer of generic pharmaceuticals with a US FDA approved 70,000 sq ft plant. In 1997, Sun Pharma invested an initial $7.5million and structured a technology transfer agreement with the loss making, $0.8 million sales turnover Caraco, that would help it bring new products to market and build sales. A similar agreement was signed in 2002 on completion of the first agreement. Stakes were bought from two large shareholders in 2004, taking the holding to over 60% from 44%, and now the stake is 75% on a diluted basis, which has been reached by technology transfer.

Based on the technology transferred out of Sun Pharma, Caraco now markets 34 ANDAs and has witnessed an increase in sales to $223 million in the year ending March 2010. 120 more ANDAs await approval from both the companies, In addition to a well-considered pipeline of generics under development. The US generic opportunity is immense, with products worth over $40 bill likely to go off patent in the next few years. For some key products, Caraco sources API from Sun Pharma's plants and competes as an integrated manufacturer. Such integration offers considerable time and cost advantages in the competitive US generics market.

In December 2010, Sun Pharma and its subsidiary offered a transaction for going private by which the company, and/or one or more of its affiliates would acquire all of the outstanding shares of Caraco common stock for $4.75 per share.


MJ Pharmaceuticals Ltd.
Equity stake, 1996; merged with Sun Pharma in 2002-03

This plant, with one USFDA approval for Cephalexin capsules and UKMHRA approvals for oral dosage forms, was acquired for the tremendous potential that the site could offer after expansion and upgradation, targating international markets.

This flagship plant is spread over 60,800 sq. mt, and has been upgraded to offer capability across dosage form lines (sterile dry powder injections, small volume injections, nasal sprays, tablets, capsules, soft gelatin caps, aerosols, ophthalmics). Our Halol plant has one of the best manufacturing sites for insulin in India, and includes Asia's largest sites for injectables and nasal sprays. This injectable site, with 7 manufacturing lines, spread over 36,000 sqft, was recently inspected and approved by the USFDA for injectables and nasal sprays.

Other important approvals include those from South African Medicines Control Council (MCC), Brazilian National Agency of Sanitary Surveillance (ANVISA) and Columbian Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA).


Gujarat Lyka Organics Ltd.
Equity stake 1996, Merged 1999

This manufacturing site for Cephalexin and 7ADCA actives has since been converted into a ISO 9002 certified, intermediates and API manufacturing site for India and traditional markets.


Tamil Nadu Dadha Pharmaceuticals Ltd.
Acquisition, 1997

Enabled a quick entry into high-growth therapy areas of interest: fertility, anticancer, anesthesiology, gynaecology, pain management. Trusted brands, processes for difficult-to-make Oncology products such as Cisplatin and Carboplatin, and a field force with existing relationships were advantages. In the subsequent years, this portfolio was totally revamped to bring new products to market, doctor coverage was improved, and a swift increase in customer rankings was seen. We revamped the product list with new products based on complex technologies, like Susten and Lupride, to earn the trust of doctors in India and world markets.

BOARD OF DIRECTORS

Our overall management and supervision is undertaken by the Board. Our day-to-day management is the responsibility of the Managing Director who is assisted by two Whole time Directors under the supervision, direction and control of the Board. A team of professionals forms the next level of management with responsibility for the divisions or functional areas that they lead.

The Board is composed of the following members

Dilip S. Shanghvi
Chairman and Managing Director

Dilip S. Shanghvi is a graduate in commerce from Kolkata University. He founded our company in 1982 and has extensive industrial experience in the pharmaceutical industry. Mr. Shanghvi is actively involved in international pharmaceutical markets and research and development functions in our company and is also the Chairman of our primary subsidiary, Caraco, in Detroit, U.S.A.

Sudhir V. Valia
Executive Director

Sudhir V. Valia is a fellow Member of Institute of Chartered Accountants of India and carries more than two decades of taxation and finance experience. He joined our company in 1994, prior to which he was in private taxation practice. In addition to being on the Board of Directors of a number of companies in our group, he is also on the Board of Directors of Caraco.

Sailesh T. Desai
Executive Director

Sailesh T. Desai is a science graduate from Kolkata University, with more than 28 years of industrial experience, 18 of which have been in the pharmaceutical industry. Mr. Desai has had comprehensive corporate affairs experience, being involved in the turnaround at Milmet prior to our acquisition of it, as well as in the early stages of our company's growth.


S. Kalyanasundaram
Chief Executive Officer
S. Kalyanasundaram is a BSc, ACA and carries almost three decades of regional/ global experience much of which has been in pharmaceuticals, largely with Glaxosmithkline, where he has held both Country, Regional and global responsibilities. As the Managing Director, GSK India, he led the GSK India turnaround; and in the regional role, he spearheaded the company's differentiated and region-specific emerging markets strategy. He also led the commencement of operations in certain emerging markets such as Vietnam, IndoChina, as well as the Wellcome New Zealand reorganization.

 
Hasmukh S. Shah
Non-Executive Independent Director

Hasmukh S. Shah has four decades of experience in senior management, and was formerly the Chairman and Managing Director of Indian Petrochemical Corporation Ltd, as well as the Vice Chairman of GE Capital and advisor to GE in India. He has had wide experience in various government departments, including as Joint Secretary to the Prime Minister, as Secretary, Post & Telegraph and as Chairman, National Institute of Design, as well as the Institute of Rural Management, Anand and the Gujarat Council of Science & Technology.

Keki M. Mistry
Non-Executive Independent Director

Keki M. Mistry is a Fellow Member of the Institute of Chartered Accountants of India and a Member of the Michigan Association of Certified Public Accountants, USA. He is the Managing Director of the Housing Development Finance Corporation Limited, widely considered to be India's leading housing finance company. He has worked as a consultant to the Commonwealth Development Corporation in various emerging markets as well as to the Asian Development Bank. He holds a number of directorships and is a member of the management committee of the Bombay Chamber of Commerce & Industry.

Ashwin Dani
Non-Executive Independent Director

Ashwin Dani is a science graduate from the Institute of Science, University of Mumbai and U.D.C.T., University of Mumbai. He also holds a Masters Degree in polymer science from University of Akron, Ohio, USA and Diploma in colour science from Rensellaer Polytechnic, Troy, New York. He is Vice Chairman and Managing Director of Asian Paints (India) Limited, one of India's leading paint companies. He also holds a number of directorships and has been nominated by the government as a Trustee on the Central Board of Trustees of the Employees Provident Fund. He is also a member of the executive committee of the Federation of Indian Chambers of Commerce and industry.
Top
S. Mohandchand Dadha
Non-Executive Independent Director

S. Mohandchand Dadha has approximately four decades of experience in the pharmaceutical industry. Mr. Dadha was Managing Director and Promoter of Tamilnadu Dadha Pharmaceuticals Ltd, which merged with Sun Pharma in April 1997.

INDIA
Customer focus: Speciality therapy area leadership

Sun Pharma pioneered speciality marketing in the Indian pharma industry when the company began in 1983. Today, we ensure we retain this edge, through our structure of customer-dedicated marketing teams and comprehensive product portfolios.

We've reached leadership in each of the therapy areas that we operate in, and have built a reputation of trust and quality with our customer.


Speciality
1998
Aug 10 - Oct 10












Psychiatrists
1
1












Neurologists
1
1












Cardiologists
5
1












Ophthalmologists

Orthopaedicians


NA

31


1

1














Gastroenterologists


6
1












Diabetologists
6
2












Nephrologists
NA
2












Consultant Physicians
16
3












Chest Physicians
8
4












Gynaecologists

Urologists

Oncologists


 

16

NA

NA


6

8

9














In the Indian prescription market, we are ranked 6th by prescription share, with market share at 3.7% and a growth rate of 20% faster than industry. Adding to market share and keeping this customer focus remains a high priority area for the company.

Sun Pharma market share up from 0.93% (Dec-92) to 3.7% (Dec-10)
1992 Market
Share indexed
to 100


US

The USD 40 billion generic market is our topmost priority. We are present in the US directly, through Sun Pharmaceutical Industries Inc., and through our subsidiaries Taro and Caraco. Between Sun Pharma, Taro and Caraco, currently over 149 filings await approval (December 2010). Our pipeline is a mix of simpler generic filings, complex filings like those for derma products, injectables or sprays and a few patent challenges.

So far, we've had success as a generic company with the advantages of several acquisitions, supported by manufacturing integration and product development in India. Our 2010 acquisition of Taro Pharma brings in manufacturing capability in Canada and Israel, and a strong list of ANDAs, specially in dermatology.

With significant balance sheet strength, we continue to be on the lookout for acquisition opportunities in the US generic pharma space, particularly for companies where we can streamline the business and create sustainable value.

Taro USA develops, manufactures and markets prescription and OTC products, primarily in the United States (as well as in Canada and Israel), and in most of these markets a dedicated field force is in place. We will now work to maximize the opportunity that this pipeline offers.

We had initially  invested $7.5 million in Caraco in 1997. The subsequent scaling up of its business saw revenues moving from US $0.8 million in 1997 to over USD 112 million in March 2009, and inspired our longer term plans for the US.  So far, Caraco has been competing as a generic manufacturer that is integrated for some of its bulk actives to Sun Pharma's API sites in India. The thirty or so ANDAs that Caraco holds registrations for, included products where it was amongst the top 3 in terms of market share prior to the cessation of manufacturing in June 2009.

On 25th June, 2009, the Food and Drug Administration seized drugs manufactured at Caraco on account of unresolved violations of cGMP requirements. Caraco has been actively working with cGMP consultants to resume manufacturing. Subsequently, Caraco entered into a Consent Decree with the FDA on September 29, 2009. Under the terms of the consent decree, Caraco's cessation of manufacturing will continue until it receives written notification from independent experts and the FDA that it is in compliance with the Consent Decree and regulations and can resume operations.

We also have a USFDA approved site in Halol, India. This large manufacturing site follows international systems and processes and can make a range of dosage forms across tablets, capsules, ophthalmic and difficult-to-make products like injectables, nasal sprays and soft gel capsules. Of specific interest is the existence of special dedicated areas to manufacture dosage forms for categories such as steroids, anticancer and hormones.

In 2005 we acquired two plants - in Cranbury, New Jersey and in Bryan, Ohio.

The Cranbury facility (the erstwhile Able Labs) offers 275,000 sq. ft. with special suites for the manufacturing of controlled substances. The controlled form manufacturing at this site ties in with the acquisition last year of a company in Hungary. Our Hungarian site (ICN Hungary, formerly known as Alkaloida) is one of the few worldwide authorized to make API for controlled substances. Over time, once the required regulatory approvals are received, we intend to compete in the US market as an integrated generic company in this high value area.

Lotions, ointments and liquids is an interesting area. Our Bryan, Ohio, facility equip us to compete in this product opportunity at a sensible cost.

ADDRESSES   
           
EU Contacts   
           
   
Netherlands                    
SUN Pharmaceutical Industries Europe B.V.
Polaris Avenue 87
2132 JH Hoofddorp,
The Netherlands
Phone: +31 23 56 85501
Fax: +31 23 56 85505
info@sunpharma-europe.nl            
   
UK          
SUN Pharmaceuticals UK Ltd.
1200 Century Way Thorpe Business Park
Colton, Leeds LS158ZA
United Kingdom
Phone: +44 (0) 808 909 8001
Fax: +44 113 341 0388
customer.support@sunpharma-europe.co.uk            
   
Italy             
SUN Pharmaceuticals Italia Srl
Via Luigi Rizzo, 8
20151 Milano,
Italia
Phone: + 39 02 33 490 793
Fax: + 39 02 33 431 842
info.italy@sunpharma-europe.it
           
   
   
Spain              
SUN Pharmaceuticals Spain S.L.
C/Bobinadora 1-5 Planta 1a Local 13
Mataro, 08302
Barcelona,
Spain
Phone: +34 93 798 02 85
Fax: +34 93 741 56 02
atencionalcliente@sunpharma-europe.es            
   
Germany         
SUN Pharmaceuticals Germany GmbH
Kandelstrasse 7
79199 Kirchzarten,
Germany
Phone: +49 7661 90 91 58-0
Fax: +49 7661 90 91 58-10
info.de@sunpharma-europe.de            
   
France       
SUN Pharmaceuticals France
34 rue Jean Mermoz
78600 Maisons Laffitte
France
Phone: +33 1 39 62 10 24
Fax: +33 1 39 62 55 29
info.france@sunpharma-europe.com


REST OF THE WORLD
An Imprint of quality across markets

The high-growth global generic markets are an exciting opportunity, and are estimated to reach $ 135 billion by 2015. Emerging markets are expected to grow at 3 times the growth rate for developed markets. (CSFB Pharma Far Marts, March 2010). In yet another 2010 report, IMS indicated that 17 high-performing pharmerging nations, that accounted for  16% of the total world market or US$123 billion in 2009, were about to overturn the established pharmaceutical world order and account for 58% of global growth by 2013 ( IMS Pharmerging shake up, 2010)

We are taking our speciality prescription products to select international markets. Currently we are present in markets across specific countries in South East Asia, South America, Russia, China, some countries across the Middle East. Manufacturing sites in Brazil, Mexico, Bangladesh and Hungary enhance our capability to compete as a local player. Taro strengthens this part of the business with a ready presence with dermatologicals in important international markets like Israel and Canada..

In each of the markets of our interest, specific speciality products are sold as branded generics that require a prescription. A 650- strong representative force is in place. In addition to a comprehensive range of products, several of our brands use complex technology, and at times we are the only branded generic for that product.

Our intent is to bring to customers in these markets the same products that have delivered value and quality in India. Products with complex technologies such as Lupride Depot (Lupreolide one and six months depot injection) and Lipodox (liposomal doxorubicin)..


API

Our API (Active Pharmaceutical Ingredients) program began in 1995 with a simple objective - facilitating the manufacture of complex formulations, products for which complete vertical integration would help the business. We currently make APIs at 9 plants, including locations in Hungary, US and Israel. Technical capability and dedicated sites to make complex API such as anticancers, peptides, sex hormones and controlled substances
are an important feature of our API business.

Over time, we have been able to take this advantage to international markets, particularly to the US.
Our recent acquisition of Taro brings to the table a strong API business manufactured out of its Haifa Bay,
Israel, site.Taro makes a comprehensive list of API including warfarin, carbamazepine, etodolac & clorazepate.

Starting with 2 actives in 1995, our API list has since expanded to over 200, and this includes a number of APIs with regulated market approvals such as US and European drug master files (DMFs)

Most of our plants are ISO 14001 and ISO 9002 approved, besides being approved by the respective foreign regulatory authorities. Every year we scale up about 25 APIs, and make a large number of filings based on the technology we develop at our research centre.

A range of APIs including complex actives like anticancer, steroids, peptides and hormones are manufactured in dedicated areas that follow international norms for systems and processes. Our buyout, in 2005, of ICN Hungary (Alkaloida) has enabled us to enter the controlled substance API manufacturing space, one of the few sites in the world to hold these approvals.


In November 2008, we acquired Chattem Chemicals, Inc., which is licensed by the DEA to manufacture Schedule 1 to 5 controlled substances. It has a facility spread over 6.5 acres in Chattanooga, Tennessee, where it manufactures a large number of controlled substances.

Our ability to make high quality, complex APIs and skills in product development and scaleup are expected to power our API strategy going ahead.

R & D

Research and Development: Creating a strong generic pipeline

At Sun Pharma, building a continually replenished pipeline of speciality generics, including differentiated generics that we can register across markets, .is vital to our growth.

Our research projects are geared to enable us develop formulations of the latest molecules and bring them to market, at a reasonable cost and ahead of competition. Focused development of generics in defined specialty areas, and creating difficult to mimic generics based on complex technologies, is key to our efforts.

Our first research center, Sun Pharma Advanced Research Center (SPARC), was set up in 1993 in Baroda in the western state of Gujarat in India.  The work done here was instrumental for the rapid growth in the subsequent period. Starting from a small base, the infrastructure at this initially 32,000 sq ft research center was used to streamline product development to bring to market on an average 40 formulations and 25 new API every year. These facilities have since been shifted to our new research campus,also in Baroda.

In 2004, a new research campus with areas for process / product development went on stream in Baroda . His Excellency, Dr. A P J Abdul Kalam, the Hon. President of India , formally inaugurated this research center in a glittering ceremony in December 2004.

This 16-acre campus with nearly 350,000 sq ft research area offers space for the development of generics meeting international development standards, including difficult to make complex generics and complex API processes, such as those for steroids and peptides.

This site houses labs that address different aspects of generic dosage form and API development. A full fledged bioequivalence center spread over 25,000 sq ft and fully equipped with 222 beds works on biostudies for submissions in India and international markets. This biostudy center has been audited by international regulatory agencies

.
In addition to an extensive library and conference areas, spacious and well equipped labs are in place for process chemistry for API development, formulation development for conventional dosage forms and complex delivery systems.

Well-equipped labs across pharmacokinetics, bioequivalence, and analytical development offer required developmental support.

A second research center in Mumbai, spread over 50,000 sq ft, develops generics for the US. This center has developed products were being made at Caraco as well as our other USFDA approved sites.

Our research commitment usually is between 7-8% of our turnover, and we've put in a total of Rs. 20 billion for generic research since 1993. Our approach to research has been incremental starting with the simple and moving on to the more complex. We began with simpler dosage forms, moved on to novel drug delivery systems and complex API.

Across areas, 85 patents have been received of 257 patents filed. Every year, we typically bring about 30 new products to the Indian market, scale up 25 API including drug master files for US and Europe, develop and file for 30 plus ANDAs for the US.

REVERSE ENGINEERING
Dosage form development

Our formulation development team has the capability to develop and bring to market in India over 40 new products every year, products that are bioequivalent to internationally available brands.

This expertise spans immediate/controlled release products as well as complex injectables and differentiated delivery systems. Simpler dosage forms worked on  include tablets, capsules, liquids, and ointments. Complex products include soft gel caps, liposome targeted drug delivery, osmotic delivery systems, inclusion complexes, meltabs, transdermals, aerosols, complex ophthalmic technologies, biodegradable depot-based formulations for 1 month/3 month release.



Facilities
    Solid oral dosage form labs
    Semisolid lab
    Nanotechnology/liposome lab
    Sterile lab for parenterals
    Aerosol area
    Packaging development lab
    Stability testing labs

PROCESS DEVELOPMENT
Leveraging Chemistry skills

Our team develops and scales up processes for APIs. The processes we develop are designed to be cost effective, plant and environment friendly. Existing production processes are also upgraded from time to time so as to make them more cost/energy effective.
These skills in API development offer us remarkable speed and efficiency so that we compete as an integrated generic manufacturer in major markets of the world.

Our process chemistry group has an enviable track record. From just 2 APIs developed and launched in 1995, the list has now grown to over 200 APIs. On an average, technology for 20-25 APIs is developed every year, and this includes projects for DMF/EDMF filing. The area of expertise includes complex chemistry such as steroids, anticancer, peptides and hormones. The Alkaloida and Chattem acquisitions have brought us strengths in the controlled substance space as well.


Expertise has been developed to effectively transfer multi-step chemical processes from the bench scale to kilo scale across a range of conventional and novel chemical reactions.

Complex Drug Technologies

We pioneered sustained delivery systems in India when we launched Lithosun SR in 1985. Since then, we have worked hard to bring to market products that use innovative drug technologies for a quality of life benefit for the patient.

Every year, we introduce about 30 new products in the Indian prescription market, a large number of these products use a delivery system or are based on a complex technology.

Branded generics based on the following delivery systems have been introduced in India, to name a few:

    Metered Dose Inhalers
    Liposomal Drug Delivery Systems
    Biodegradable Depot Formulations
    Controlled release formulations
    Osmotic release formulations
    Nasal sprays
    Melt tabs

LABS AT SPARC

At our research center, SPARC, we have labs across :

    Organic synthesis - Separate labs for synthesis of new molecular entities and for process development with facilities for synthesis of complex peptide, steroids, cephalosporins and hormones.
    Formulation development - conventional / novel dosage forms (orals, transdermals, inhalers, targeted drug delivery).
    Biotechnology
    Analytical method development
    Pharmacokinetics
    Bioequivalence


Organic synthesis
Medicinal Chemistry

At these labs we synthesize new molecular entities for different therapeutic targets for new drug discovery programs. We have facilities for parallel synthesis and in-silico drug design.

Process development

At these labs, we develop chemical processes for speciality APIs that go into speciality dosage forms. A large part of our dosage form business, both in India and in the US at Caraco, uses the APIs that we have developed and manufactured in-house. This helps us to compete as an integrated pharma company across these major markets. We've also developed processes for technically complex actives that are close to patent expiry. For several products, we have developed environment-friendly, higher yield or cost-effective processes. All APIs are developed to comply with international pharmacopoeial standards or to meet definite customer specifications.

Peptides

Several peptide based projects such as the anticancer / fertility peptide leuprolide have reached India and developing markets based on developmental work at the research center. Several more projects are in the pipeline, and these address fairly interesting international opportunities.

Dosage form development

We apply advances in pharmaceutical technology to create dosage forms that offer a patient benefit. Expertise spans conventional as well as novel drug delivery systems based on established technologies. Several products with a delivery system advantage have earned us a marketplace edge.

Dosage form development

We apply advances in pharmaceutical technology to create dosage forms that offer a patient benefit. Expertise spans conventional as well as novel drug delivery systems based on established technologies. Several products with a delivery system advantage have earned us a marketplace edge.

Conventional Products

    Tablets
    Capsules
    Injectables

Complex products

    Injectables for difficult to formulate products (peptides such as Lupreolide and Octreotide).
    Depot injectables involving month-long or three-month long drug release.
    Injectables for liposomal based products (liposomal doxorubicin).
    Sustained release products (Zeptol CR, Monotrate OD, Prazopress XL (with a micropore based drug dissolution and release) , Urotel XL, Dicorate ER, Latocom OD).

Longer term projects based on known technology in the areas of

    Controlled / Sustained release - gastric retention systems and products for very highly soluble drugs.
    Biodegradable membranes such as Lupride Depot (one month or three month depot formulations of the peptide lupreolide).
    Targeted drug delivery products like Lipodox (Targeted liposome doxorubicin).
    Dry powder inhalers.

Analytical Development

Extensive facilities with the latest instrumentation for establishing the integrity and stability of pharmaceuticals and APIs are in place. Expertise in method development for impurity profiling and identifying degradation products has been built up.

Facilities

    Worldclass equipment for instrumental, chemical and microbiological analysis.
    Equipment include: NMR, XRD, LC-MS/MS, HPLCs etc.

Clinical Research

Modern facilities at our clinical research center have been approved by the drug regulatory authorities in India for Bioavailability / Bioequivalence (BA / BE) testing.


A well-established Clinical Pharmacology Unit (CPU) offers facilities for BA/BE studies to be carried out in accordance with Good Clinical Practice (GCP).The labs have been audited by an international clinical research firm.

Pharmacokinetics

A full-fledged Pharmacokinetics team works on preclinical pharmacokinetic studies i.e. studies that track the absorption, distribution, metabolism and excretion (ADME) for products that we introduce for India and the international markets, and for the new chemical entities in the drug discovery program.

BUSINESS DEVELOPMENT

Sun Pharma is an international speciality pharma company. We have a significant presence in the US through our subsidiary Caraco. In the rest of world markets, we have a strong ground network of 600 committed field force in 41 countries, with a pipeline of over 2600 products of which 1600 are registered and marketed. We have 3300-person strong sales team in India distributing through 2400 stockists, We are now at a stage of rapid growth across geographies spanning Russia and CIS countries, China and South east Asia, Africa and Latin America, where we are rapidly emerging as a branded generic company of choice.

In India, we are among the largest pharmaceutical companies and command a 3.7% market share (ORG IMS Stockist Audit, Dec 2010). In India, we market over 500 products through 18 speciality marketing divisions that are built around chronic therapy areas. Typically, every year we introduce 25-30 new products. All of these are developed in-house supported by strong bulk synthesis, formulation development, bioequivalence and regulatory teams. CMARC (A prescription audit agency) has ranked us as No.1 in key chronic therapy areas of Neuropsychiatry, Cardiology, Gastroenterology, Orthopedics and Ophthalmology. We rank among the top 5 companies for Diabetology, Respiratory, Pain, Cancer and Gynecology.

In-Licensing

We look at partnering and collaborating as an important strategic approach that will complement our growth in India and international markets. Our constant need is to add to our speciality product portfolio for prescription leadership in India. We also seek to strengthen our presence, with a complete basket of speciality products, in Russia and CIS countries, China and South East Asia, Africa, Brazil and Mexico.

We are currently interested in in-licensing products that are already marketed or are in late stage clinical development in our key therapy areas. We seek products that leverage our core strengths and complement our existing product portfolio in the following therapy areas:
 
CNS disorders
Cardiology
Diabetes and Metabolic disorders
Gastroenterology
Ophthalmology
Oncology
Pain
Allergy, Asthma and Inflammation
Gynecologicals

We also have strategic interest in licensing biosimilar products and new products based on recombinant/humanized monoclonal antibody technology that find use in these therapy areas

We seek to establish a long term, mutually rewarding relationship based on exclusive marketing rights business model for the above listed geographies, as well as co-marketing or strategic alliances for co-development including clinical trials of products for necessary regulatory approvals.

Out-licensing

Our formulation development expertise enables us to develop complex generic products which are bioequivalent, sustained release oral dosage forms and long acting injectable depot formulations.

We offer a range of dosage forms for oral, injectable, topical and transdermal routes developed through non-infringing routes and/or patented routes.

Our Organic synthesis team develops highly complex bulk actives like Peptides, Hormones, Steroids, Anticancer drugs and Cephalosporins through non-infringing routes and/or patented routes. We offer over 150 bulk actives manufactured at USFDA/UK MHRA approved sites.

We seek out-licensing opportunities for our speciality generics, super generics, and bulk drugs for global markets.
 
CVS
CNS
Pain
Cancer
Gynecologicals
Allergy, Asthma other respiratory diseases

Our Organic synthesis team develops highly complex bulk actives like Peptides, Hormones, Steroids, Anticancer drugs and Cephalosporins through non-infringing routes and/or patented routes. We offer over 150 bulk actives manufactured at USFDA/UK MHRA approved sites.

We seek out-licensing opportunities for our speciality generics, super generics, and bulk drugs for global markets.

Job Opening in Sun Pharma : Click Here

For Job Apply Click here:Apply Now

ADDRESSES EU Contacts    
               
Corporate Office    
               
   
Sun Pharma                        
Acme Plaza,
Andheri - Kurla Rd, Andheri (E),
Mumbai - 400 059.            
Research Centres
Sun Pharma Advanced Research Centre (SPARC)
Akota Road,
Akota,
Baroda - 390 020.

Sun Pharmaceutical Advanced Research Centre (SPARC)
17 B Mahal Industrial Estate,
Mahakali Caves Rd Andheri (E),
Mumbai - 400 093.
Sun Pharmaceutical Advanced Research Centre (SPARC)
F.P No. 27,
Part Survey No. 27 C.S No.1050,
Village Tandalja,
Baroda - 390 020.
           
Dosage Form Plants
Sun Pharma
C1/2710 GIDC Phase-III,
Vapi - 396 195,
Gujarat.

Sun Pharma
Survey No. 214 and Plot 20,
Govt. Industrial Area, Phase-II,
Piparia, Silvassa - 396 230.
Sun Pharma
Halol - Baroda Highway,
Halol - 389 350.

Alkaloida Chemical Company Zrt.
H - 4440 Tiszavasvari,
Kabay Janos u. 29.
Hungary.
Partnerships
Sun Pharma
Plot No. 223,
Span Industrial Complex,
Near R.T.O Check Post,
Dadra - 396 191 (U.T).

Sun Pharma
6-9, EPIP Kartholi,
Bari Brahmana,
Jammu, J&K.
Joint Venture

Sun Pharma
House No. 4, Road No. 16-a,
Near Gulshan Post Office,
Gulshan-1,
Dhaka, Bangladesh.
Subsidiary

Sun Pharmaceutical Industries Inc.
705 E. Muberry St.,
Bryan, OH 43506,
USA.
Sun Pharmaceutical Industries Inc.
270 Prospect Plains Rd.,
Cranbury, NJ 08512,
USA
   
API Plants
Sun Pharma
Plot No. 25,
GIDC, Phase-IV,
Panoli - 395 116.

Sun Pharma
A-7 & A-8,
MIDC Industrial Area,
Ahmednagar - 414 111.

Sun Pharma
Sathammai Village, Karunkuzhi Post,
Maduranthakam T.K., Kanchipuran District,
Tamil Nadu - 603 303.

Sun Pharma
Plot No. 4708, GIDC,
Ankleshwar - 393 002.
Sun Pharma
817/A, Karkhadi,
Ta Padra,
Dist. Vadodara - 391 450.
Alkaloida Chemical Company Zrt.
H-4440 Tiszavasvari,
Kabay Janos u. 29.
Hungary.

EU Contacts

Netherlands

Sun Pharmaceutical Industries Europe BV
Polaris avenue 87,
2132 JH Hoofddorp,
The Netherlands.
Phone: +31 23 56 85501
Fax: +31 23 56 85505
info@sunpharma-europe.nl

UK

SUN Pharmaceuticals UK Ltd.
1200 Century Way Thorpe Business Park
Colton, Leeds LS158ZA
United Kingdom
Phone: +44 (0) 808 909 8001
Fax: +44 113 341 0388
customer.support@sunpharma-europe.co.uk

Italy

SUN Pharmaceuticals Italia Srl.
Via Luigi Rizzo, 8
20151 Milano,
Italia
Phone: + 39 02 33 490 793
Fax: + 39 02 33 431 842
info.italy@sunpharma-europe.it

Spain

SUN Pharmaceuticals Spain S.L.
C/Bobinadora 1-5 Planta 1a Local 13
Mataro, 08302
Barcelona,
Spain
Phone: +34 93 798 02 85
Fax: +34 93 741 56 02
atencionalcliente@sunpharma-europe.es

Germany

SUN Pharmaceuticals Germany GmbH
Kandelstrasse 7
79199 Kirchzarten,
Germany
Phone: +49 7661 90 91 58-0
Fax: +49 7661 90 91 58-10
info.de@sunpharma-europe.de

France

SUN Pharmaceuticals France
34 rue Jean Mermoz
78600 Maisons Laffitte
France
Phone: +33 1 39 62 10 24
Fax: +33 1 39 62 55 29
info.france@sunpharma-europe.com

Products of Sun

AB-PHYLLINE  MILBORN 
ACAMPROL  MILFLOX PLUS 
ACUCAL  MILFLOX-DM 
ACUDRIN  MIRTAZ 
ADCAPONE  MODALERT 
ADDWIZE  MOFAX 
ADFOVIR  MONDESLOR 
ADPACE-4  MONOTRATE 
AEROTAZ DISK  MONOTRATE-OD 
AFDURA  MONOTRATE-SR 
ALCAINE-MPS  MONTEK 
ALCOLIV  MONTEK PLUS 
ALZOLAM  MONTEK-LC 
ALZOLAM-SR  MOXIBACT 
AMIXIDE  MOZAX 
AMIXIDE-H  MOZAX-MPS 
AM-LAQER  MQF 
AMLOBET  MUFECT 
AMLOSUN  MUVERA 
ANABREZ  NARATREX 
ANDROBLOK  NASOMET 
ANOFER  NAXDOM 
ANXOZAP  NEPALACT 
AQUAMIDE  NEUCOBAL 
AQUAZIDE  NEUCOBAL PLUS 
ARAVON  NEUCOBAL-FORTE 
ARGIPRIME  NEUCOBAL-G 
ARPIZOL  NEUCOBAL-OD 
ARTISID  NEUGABA 
ATCARDIL  NEUGABA-ER 
ATCURON  NEUGABA-M 
ATTENTROL  NEW TRIGLUCORED FORTE 
AZELAST  NEXIPRIDE 
AZTATIN  NEXITO FORTE 
AZTOR-ASP 150  NEXITO 
BECLOCORT-N  NEXITO PLUS 
BENFOMET  NEZALAST 
BENFOMET PLUS  NITREST 
BENZADAY  NITROJECT 
BETACAP  NITROSUN 
BETACAP PLUS  NORMOLIP 
BETACAP-TR  OCTRIDE 
BETATROP  OD-PHYLLIN 
BETAVERT  OLEANZ FORTE 
BIVAFLO  OLEANZ 
BRONKONAT  OLEANZ TAB 
BUDEZ ENEMA  OLMEZEST-AM 
BUDEZ INHALER  OLMEZEST-H 
BUDEZ-CR  ONCOTREX 
BUPRON-XL  OSTOSPRAY 
CABERLIN  OVURELIX 
CAFIRATE  OXETOL 
CAMOPAN  OXIPLAT 
CANSOFT  PALIRIS 
CANSOFT-CL  PALONEW 
CAPSAIN-P  PANLIPASE 
CARBICEF  PANTOCID FAST 
CARDIJECT  PANTOCID 
CARDIVAS  PANTOCID-D 
CARDIVAS-CR  PANTOCID-DSR 
CARMAZ  PANTOCID-HP 
CARMAZ KID  PANTOCID-IT 
CARTISHINE  PANTOCID-L 
CAXETA  PARKITANE 
CELACT  PARKITIDIN 
CERELOID  PAXIDEP 
CERNOS  PEPLER 
CERNOS DEPOT  PHOSFORID 
CETRIZET  PILOMAX 
CETRIZET-D  PIOGLIT 
CHLORPROMAZINE TAB  PIOGLIT-MF FORTE 
CIPTAM  PIOGLIT-MF 
CIPTAM-CT  PIOGLUCORED FORTE 
CLENZ  PRAMIPEX 
CLOFRANIL  PRAZEP 
CLOPILET  PRAZOPRESS 
CLOPILET-A  PRAZOPRESS-XL 
COBAMET-OD  PRIMEROSE 
COGNITOL  PRIMOX 
COLOTECAN  PRODEP 
COMBIPLET  PROLINATE 
COMBITIDE  PROLOMET-AM 
CONTIFLO-OD-F  PROLOMET-R 
COZABAL  PROMASUN 
DARILONG  PROMOLET-AM 
DAZIT  PULMOZA 
DAZOLIC  PUREGEST 
DEPOPRED  PYRODEX 
DIABA  QUDICT 
DIABA-M  QUTIPIN-SR 
DILTIACT  RANOZEX 
DIREC-2  RAPIFOL 
DISTENIL  RAPILAC 
DOCEFREZ  RASALECT 
DOLOTRAM  RELIF 
DONAMEM  REPACE 
DONECEPT  REPACE-A 
DRONIS  REPACE-AF 
DULANE-M  REPACE-H 
DURACARD  REPALOL 
DURALAST  REPALOL-H 
DUZAC  RESTOFOS 
DUZELA  RETENSE 
DUZELA-M  REVLAMER 
D-VENIZ  REVOCON 
D-VOID  RIDAZIN 
DYNOLAP  RIFAGUT 
E 2 VAGINAL TAB  RIMAREX 
E2 GEL  RIOBANT 
EDEGRA  ROLSICAL PLUS 
ELEGELIN  ROPARK 
ELIWEL  ROXETOMIN 
EMSETRON  ROZAVEL 
ENCORATE CHRONO  ROZAVEL-EZ 
ENCORATE  ROZAVEL-F 
EPIVAL  RUNAC GEL 
ETIREST  RUNAC 
ETOMIN  RUNAC-P 
ETOSHINE  SENORM 
ETOSHINE-MR  SENORM-LA 
EXODEP  SIZODON FORTE 
EXZILOR  SIZODON PLUS 
EZACT  SIZODON-LS 
EZENTIA  SIZODON-MD 
EZOMA  SIZOPIN 
FAMOCID  SKELACT 
FEBUGET  SKELEBENZ 
FEBUTAZ  SMOQUIT-SR 
FELCAM-DT  SNEPDOL 
FELDEX  SOFALCO 
FENDROP  SOMPRAZ-L 
FENTOIN-ER  SPASTHELINE 
FERTIGYN  SPILACTONE-T 
FIBATOR  STEROTOP 
FIBATOR-EZ  STROCIT 
FIBATOR-LS  STROCIT-M 
FIBMET  STROZAGEL 
FLEXITAL  SUMINAT 
FLEXURA  SUN PRAZIN 
FLEXURA-D  SURFACT 
FLOCY DPS  SUSTEN 
FLOEASE  SYNCAPONE 
FLUTINOL  SYNDOPA PLUS 
FLUVOXIN  SYNDOPA 
FLUVOXIN-CR  SYNDOPA-CR 
FOMTIDE  TACRIMUS FORTE 
FULNITE  TACRIMUS 
GABANTIN FORTE  TAMDURA 
GABANTIN  TAMFLO 
GABANTIN PLUS  TAMFLOX 
GALINERVE-M  TAMIACIN 
GEMER FORTE  TAMLET 
GEMER  TAMSPAR 
GEMER-P  TAZOTOP FORTE 
GEMER-PL  TAZOTOP 
GEMTAZ  TERLYZ 
GLIOTEM  THALOMA 
GLIPIMET FORTE  THEODER 
GLIPIMET  THIOACT 
GLUCORED FORTE-SR  THIOACT-D 
GLUCOSAFE  THROMBONIL 
GLYPRIDE  THROMBOSPRIN 
GLYTEARS  TIDIGESIC 
GRANISET  TIOTROP 
GRAVITOR  TIZAFEN 
HP-KIT  TIZAN 
HYDROQUIN  TOPIROL 
HYTROL  TORLACTONE 
HYTROL-AM  TRAPEX 
IDROFOS  TRAPIC E 
IMALEK  TRAPIC MF 
IMPRAMINE  TRAPIC 
INAPURE  TRAZALON 
INHEP  TRAZINE 
IROVEL  TRAZINE-H 
IROVEL-H  TRAZINE-S 
IVEPRED  TRAZINE-SC 
KETAM  TRIGLUCORED FORTE 
KORANDIL  TRILOPACE 
KRIMSON  TRINORM 
LACOSET  TRIOLMEZEST 
LACTIHEP POWDER  TRIPHEN 
LACTIHEP SYR  TROPAN 
LAMOSYN  ULCERFATE 
LESURIDE-OD  ULFAST 
LETROZ  URSOCOL 
LEVIPIL  UTODIN 
LIOFEN  VECURON 
LIOFEN-XL  VENIZ-XR 
LIPODOX  VERGLOB 
LISOTEC  VERIZET-D 
LITHOSUN  VERNACE 
LOBAZAM  VOLIBO 
LOFECAM  VOLUMIN 
LOMIBACT  VORAZE 
LOTENSYL  VORIZEF 
LOTENSYL-AT  VSL-3 
LUBOWEL  WINOLAP N-SPY 
MAXGALIN-ER  XELFLO 
MAXGALIN-M  XTRAGLO 
MAXOZA  ZEMPRED CRM 
MAXTIB  ZEMPRED 
MEBIZ-SR  ZEPTOL 
MEGABROM  ZIMBA 
MESACOL  ZIPSYDON 
MESACOL SUPP  ZITOTEC 
MESACOL-OD  ZOBONE 
METHIMEZ  ZOLNITE-1 
METNIMEZ  ZOLNITE-2 
METOSARTAN  ZOROVON 
MIFEPRIN  ZOSERT 


Previous Page Next Page

People Searching On This Page:
  • Glypride2 teb...parma
  • sunpharmaceutical company in india gujarat
  • sunpharma piparia products
  • rizo dsr compani of manufacturer
  • Nasal spary Aerosol Department Sunfarma
  • Sun Pharmaceutical Industries in Vapi, Gujarat,
  • tab.prolomet xl 50 related bd product
  • san chem pharma pvt. ltd halol product
  • bay online qudict tab
  • addwize od 18 out of stock in kolkata medical store days medical
  • benfomet tablets
  • SunPharma Panoli
  • account mps.com.br loc:IN
  • info innovaction.cl loc:IN
  • info sun-new.com loc:IN

Related Pages


Cipla Pharmaceuticals Limited

Cipla Pharmaceuticals Limited

Articles | Pharma Companies | Maharashtra
Date:
02-May-2012  Views: 18991

In 1935, he set up The Chemical, Industrial & Pharmaceutical Laboratories, which came to be popularly known as Cipla. He gave the company all his pate ...
 Cadila Pharmaceuticals Limited

Cadila Pharmaceuticals Limited

Articles | Pharma Companies | Gujarat
Date:
01-May-2012  Views: 34427

We are one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. As an integrated heal ...
USV Pharmaceutical Limited

USV Pharmaceutical Limited

Articles | Pharmaceutical Drugs
Date:
02-Dec-2011  Views: 31842

We are a 50 year old leading healthcare company which began as a joint venture with USV&P Inc. USA, a subsidiary of Revlon. Our product offering today ...
Medical Representative - MR - BE –Sundyota Numandis Pharmaceuticals Pvt. Ltd

Medical Representative - MR - BE –Sundyota Numandis Pharmaceuticals Pvt. Ltd

Jobs | Medical Representative | Ahmedabad
Date:
01-May-2011  Views: 5134

Will implement mktg strategies&campaigns for product promotion to doctors,effective in-clinic presentation to doctors,identifying&promoting right prod ...
Vacancy for Assistant in Sales Administration @ Sun Pharmaceuticals

Vacancy for Assistant in Sales Administration @ Sun Pharmaceuticals

Jobs
Date:
07-Jul-2010  Views: 3255

Checking & validating basic tour program, expense statement, daily report etc. ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

4  + 4 =     
Comments
People Searched About:
Glypride2 Teb...Parma   |   Sunpharmaceutical Company In India Gujarat   |   Sunpharma Piparia Products   |   Rizo Dsr Compani Of Manufacturer   |   Nasal Spary Aerosol Department Sunfarma   |   Sun Pharmaceutical Industries In Vapi, Gujarat,   |   Tab.Prolomet Xl 50 Related Bd Product   |   Benfomet Tablets   |   Sunpharma Panoli   |   Account Mps.Com.Br Loc:IN   |   Info Innovaction.Cl Loc:IN   |   Info Sun-New.Com Loc:IN   |   Info Ijclinic.Com Loc:IN   |   Info Inca.Pl Loc:IN   |   Info Latax.Nl Loc:IN   |   Info V-K.Nl Loc:IN   |   Order Febutaz 40   |   Info Pharma56.Com   |   Sun Pharma Ltd Karkhadi   |   Lesuride MPS - Sun Pharma   |   Sun Pharmaceuticals/Gujarat   |  
Google : 1638 times | Yahoo : 20 times | Bing : 227 times |